Nebuliser systems for drug delivery in cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Daniels, Tracey ^a   Mills, Nicola ^b   Whitaker, Paul ^c  

^a YORK TEACHING HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; CARBENICILLIN; COLISTIN; DORNASE ALFA; SODIUM CHLORIDE; TOBRAMYCIN; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; CROMOGLYCATE DISODIUM; DEOXYRIBONUCLEASE I; RECOMBINANT PROTEIN; SALBUTAMOL;

ADAPTIVE AEROSOL DELIVERY NEBULISER SYSTEMS; AEROSOL; AREA UNDER THE CURVE; BREATHING PATTERN; BRONCHOCONSTRICTION; CLINICAL OUTCOME; COMPARATIVE STUDY; COUGHING; CYSTIC FIBROSIS; DEVICE FAILURE; DISEASE BURDEN; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SPUTUM LEVEL; DRUG UPTAKE; FLOW RATE; FORCED EXPIRATORY VOLUME; GAMMA SCINTIGRAPHY; HEMOPTYSIS; HUMAN; ISOTOPE LABELING; MAXIMUM CONCENTRATION; MEDICAL TECHNOLOGY; META ANALYSIS; PARTICLE SIZE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY AIRFLOW; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT DURATION; ULTRASOUND; VIBRATING MESH TECHNOLOGY NEBULISER SYSTEMS; VOICE CHANGE; MEDICATION COMPLIANCE; NEBULIZER;

AEROSOLS; ALBUTEROL; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CARBENICILLIN; COLISTIN; CROMOLYN SODIUM; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG DELIVERY SYSTEMS; HUMANS; MEDICATION ADHERENCE; NEBULIZERS AND VAPORIZERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SALINE SOLUTION, HYPERTONIC; TOBRAMYCIN;

EID: 84886814125     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007639.pub2     Document Type: Review

References (88)

1. Byrne NM, Keavey PM, Gould FK, Spencer DA. Comparison of lung deposition of colomycin using the halolite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Archives of Disease in Childhood 2003;88(8):715-8.
2. Spencer DA, Byrne N, Keavey PM, Snowdon V, Hawkins T. Radionucleotide assessment of lung deposition of nebulised antibiotics in patients with cystic fibrosis [abstract]. Proceedings of 24th European Cystic Fibrosis Conference 2001 June 6-9; Vienna, Austria. 2001:P75.
3. Spencer DA, Byrne N, Keavey PM, Snowdon V, Hawkins T. Radionuclide assessment of lung deposition of nebulised antibiotics in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 2001;Suppl 22(32):314-5.
4. Spencer DA, Byrne N, Perry J, Gould K. Microbilolgical assessment of antibiotic deposition using two nebuliser systems in patients with cystic fibrosis [abstract]. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P219.
5. Clavel A, Boulamery A, Bosdure E, Luc C, Lanteaume A, Gorincour G, et al.Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis. Journal of Cystic Fibrosis 2007;6(2):137-43.
6. Devadason SG, Everard ML, Linto JM, Le Souef PN. Comparison of drug delivery from conventional versus "venturi" nebulisers. European Respiratory Journal 1997;10(11):2479-83.
7. Devadason SG, Huang T, Walker SL, Troedson R, Le Souef PN. Lung deposition of rhDNase in children children with cystic fibrosis using the Halolite adaptive aerosol delivery (AAD) systems and Pari LC+ nebulizer [abstract]. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna. 2001:P84.
8. Conway SP, Dodd ME, Marsden RJ, Paul EA, Weller PH. Comparison of compliance in Cystic Fibrosis patients using either a Halolite adaptive aerosol delivery (AAD) system of a conventional high output nebuliser system [abstract]. Journal of Cystic Fibrosis 2002;1 SUPPLEMENT 1:S67:P161.
9. Dodd M, Conway S, Marsden R, Paul E, Weller P. Interaction between bronchodilators and nebuliser device in Cystic Fibrosis patients taking Colistin using a halolite adaptive aerosol delivery (AAD) system compared to a high output conventional nebuliser system [abstract]. Journal of Cystic Fibrosis 2002;1 SUPPLEMENT 1:S106.
10. Dodd ME, Conway S, Marsden R, Weller P. Interaction between aerosol delivery system and bronchodilators in CF patients taking colistin [abstract]. Pediatric Pulmonology 2002;34(S24):321.
11. Dodd ME, Conway S, Marsden RJ, Weller PH. Interaction between aerosol delivery system and bronchodilators in CF patients taking colistin [abstract]. Thorax 2002;57(Suppl 3):iii39.
12. Marsden R, Conway S, Dodd M, Edenborough F, Paul E, Rigby A, et al.A multi-centre, randomised study comparing the halolite adaptive aerosol delivery system with a high output nebuliser system in patients with Cystic Fibrosis [abstract]. Journal of Cystic Fibrosis 2002;1 SUPPLEMENT 1:S105-6: P120.
13. Marsden R, Conway S, Edenborough F, Rigby A, Taylor C, Weller P. Comparison of the halolite adaptive aerosol delivery (AAD) system with a high output nebuliser system in CF patients [abstract]. Pediatric Pulmonology 2002;34(S24):320-1.
14. Marsden RJ, Conway SP, Dodd ME, Edenborough FP, Rigby AS, Taylor CJ, et al.Comparison of the halolite adaptive aerosol system with a high output nebuliser system in cystic fibrosis patients [abstract]. Thorax 2002;57(Suppl 3):iii80.
15. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, et al.A comparison of peak sputum concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997;111(4):955-62.
16. Elkins MR, Bye PTP. Comparison of Pari LC-Star and -Plus nebulisers delivering 2.5mg recombinant human deoxyribonuclease (rhDNase) [abstract]. Journal of Cystic Fibrosis 2006;5 Suppl 1:S42.
17. Fiel SB, Fuchs HJ, Johnson C, Gonda I, Clark AR. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. Chest 1995;108(1):153-6.
18. Geller D. Aerosolized dornase alpha in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease?. Pediatric Pulmonology 1997;24(2):155-8.
19. Geller DE, Eigen H, Fiel S, Lamarre A, Konstan M, Johnson C. Aerosolized dornase alpha in cystic fibrosis: Smaller particle size may improve outcome in patients with mild obstructive lung disease [abstract]. Israel Journal of Medical Sciences 1996;32 Suppl:S35.
20. Geller DE, Eigen H, Fiel SB, Clark A, Lamarre AP, Johnson CA, et al.Effect of smaller droplet size of dornase alpha on lung function in mild cystic fibrosis. Pediatric Pulmonology 1998;25(2):83-7.
21. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003;123(1):28-36.
22. Wilmott RW, Chatfield B, Dyson M, Geller D, Milgram L, Noone PG, et al.Aerodose improves TOBI delivery in cystic fibrosis [abstract]. Pediatric Pulmonology 2001;32(S22):292.
23. Griese M, Kappler M, Eismann C, Mazurek H, Denk O, Goedings P, et al.Pulmonary delivery of tobramycin by an investigational EFlow electronic nebulizer saves 50% of the drug, and results in equivalent or improved tobramycin safety levels in plasma and sputum [abstract]. Pediatric Pulmonology 2009;44(S32):300, Abstract no: 252.
24. Hubert D, Leroy S, Dominique S, Kovarik J. Pharmacokinetic comparison of inhaled tobramycin (TOBI) via Pari eFlow rapid or Pari LC Plus nebulizers in cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2007;6 SUPPLEMENT 1:S12.
25. Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, et al.Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Journal of Cystic Fibrosis 2009;8(5):332-7.
26. Tavakkol A, Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, et al.Tobramycin inhalation solution (TOBI) administered via Pari Eflow Rapid nebuliser may yield a higher therapeutic ratio vs Pari LC Plus jet nebuliser in cystic fibrosis patients [abstract]. Pediatric Pulmonology 2007;42(S30):289.
27. Kastelik JA, Aziz I, Wright GA, Davies M, Morice AH. Comparitive assessment of aerosol delivery in cystic fibrosis [abstract]. Thorax 2000;55(Suppl 3):A77.
28. Kastelik JA, Davies M, Wright GA, Aziz I, Morice AH. Radiolabelled DTPA as a tool to study nebuliser performance: a comparison of two systems in cystic fibrosis and healthy volunteers [abstract]. Pediatric Pulmonology 2000;30(S20):247.
29. Kastelik JA, Wright GA, Aziz A, Davies M, Avery GR, Paddon AJ, et al.A widely available method for the assessment of aerosol delivery in cystic fibrosis. Pulmonology Pharmacology & Therapeutics 2002;15(6):513-9.
30. Köhler E, Sollich V, Schuster R, Hühnerbein. Lung deposition in CF patients using ultrasonic or jet nebulising [abstract]. XIIIth International Cystic Fibrosis Conference; 2000 4-8 June, Stockholm, Sweden. 2000:144.
31. Köhler E, Sollich V, Schuster R, Wonka V, Jorch G. Lung deposition following electronically breath controlled inhalation and manually triggered conventional inhalation in CF patients [abstract]. Journal of Cystic Fibrosis 2004;3 SUPPLEMENT 1:S65.
32. Köhler E, Sollich V, Schuster-Wonka R, Hühnerbein J. Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebuliser. Journal of Aerosol Medicine 2003;16(1):37-46.
33. Lenney W, Edenborough F, Kho P, Kovarik JM. Lung deposition of inhaled tobramycin with eFlow rapid/LC plus jet nebuliser in healthy and cystic fibrosis subjects. Journal of Cystic Fibrosis 2011;10(1):9-14.
34. Marshall L, Reinhardt C, Lundberg T, Francis P, Khafagi F. Comparison of therapeutic nebuliser performance in cystic fibrosis using Tc-99m DTPA aerosol [abstract]. Australian and New Zealand Journal of Medicine 1992;22(6):726.
35. Marshall LM, Francis P, Khafagi FA. Aerosol deposition in cystic fibrosis using an aerosol conservation device and a conventional jet nebuliser. Journal of Paediatrics and Child Health 1994;30(1):65-7.
36. Newman SP, Woodman G, Clarke SW. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax 1988;43(4):318-22.
37. Shah PL, Scott SF, Geddes DM, Conway S, Carr S, Wallis C, et al.An evaluation of two aerosol delivery systems for rhDNase [abstract]. Israel Journal of Medical Sciences 1996;32 Suppl:S222.
38. Shah PL, Scott SF, Geddes DM, Conway S, Watson A, Nazir T, et al.An evaluation of two aerosol delivery systems for rhDNase. European Respiratory Journal 1997;10(6):1261-6.
39. Thomas SH, O'Doherty MJ, Graham A, Page CJ, Blower P, Geddes DM, et al.Pulmonary deposition of nebulised amiloride in cystic fibrosis:comparison of two nebulisers. Thorax 1991;46(10):717-21.
40. Westerman EM, Boer AH, Brun PP, Roldaan AC, Frijlink HW, Heijerman HG. Aerosolization of tobramycin (TOBI) with the PARI LC plus reusable nebulizer: which compressor to use? Comparison of the CR60 to the portaneb compressor. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2008;21(3):269-80.
41. Westerman EM, Touw DJ, Heijerman HG. Portaneb or CR60? Inhalation of tobramycin (TOBI) with the Pari LC Plus nebuliser: an in-vivo pilot study [abstract]. Journal of Cystic Fibrosis 2007;6 SUPPLEMENT 1:S39.
42. Conway SP, Watson A, Pond MN, Booth R, Ghonheim A. Sputum gentamycin levels after delivery by rotahaler and nebuliser [abstract]. Pediatric Pulmonology 1993;16(SUPPLEMENT S9):175.
43. Crowther Labris NR, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT. Dry powder versus intravenous and nebulized gentamycin in cystic fibrosis and bronchiectasis. A pilot study. American Journal of Respiratory and Critical Care Medicine 1999;160(5):1711-6.
44. Dolovich M, Eng P, Rhem R, Guo X, Labris R, Thabane L. Does particle size influence distribution of inhaled therapy in the presence of airways obstruction: a 3D PET study of the lung in cystic fibrosis [abstract]. Proceedings of American Thoracic Society International Conference; 2005 May 20-25, San Diego, USA. 2005:A377.
45. Faroux B, Itti E, Pigeot J, Isabey D, Meignan M, Ferry G, et al.Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study. American Journal of Respiratory and Critical Care Medicine 2000;162(6):2265-71.
46. Hung JCC, Spring M, Hambleton G, Super M. A preliminary study on the delivery of gentamycin dry powder to the lung of children with cystic fibrosis [abstract]. 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:P53.
47. Johnson JC, Waldrep JC, Dhand R. Aerosol delivery of recombinant human DNase 1. Comparison of a vibrating mesh nebulizer with a jet nebulizer [abstract]. American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A82.
48. Kovaleva LF, Gembitskaya TE, Zaremba IA. The optimization of the therapy in cystic fibrosis (CF) patients using nebuliser [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6- 9; Vienna, Austria. 2001:P86.
49. Laube BL, Jashnani R, Dalby RN, Zeitlin PL. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000;118(4):1069-76.
50. Mallol J, Rattray S, Walker G, Cook D, Robertson CF. Aerosol deposition in infants with cystic fibrosis. Pediatric Pulmonology 1996;21(5):276-81.
51. Mallol J, Robertson CF, Cook K, Kaymakci B. Nebulised gentamycin in children with cystic fibrosis: enhancing antibiotic lung deposition by increasing flow rate and fill volume. Journal of Aerosol Medicine: Deposition, Clearance and Effects in the Lung 1997;10(4):331-40.
52. Militz S, Feilcke M, Schroter C, Kraxner A, Eismann C, Griese M, et al.E-flow rapid: improved lung function and patient satisfaction with more volume delivered to the lungs during inhalation therapy in cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2008;7 SUPPLEMENT 2:S67.
53. Moss RB, Mayer-Hamblett N, Daines C, Hale K, Gibson RL, Anderson P, et al.Randomised, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatric Pulmonology 2005;39(3):209-18.
54. Mulrennan SA, Moon TM. Prodose nebuliser usage compared with usual nebuliser in cystic fibrosis patients [abstract]. American Thoracic Society International Conference; 2004 May 21- 26; Florida, USA. 2004:A391.
55. Podolec Z. Pneumodosimeter - the application of BCTS method (bronchial control treatment systems) to breath-controlled application of medicine aerosols in water solutions to persons suffering from mucoviscidosis [abstract]. 24th European Cystic Fibrosis conference. 2001.
56. Potter RW, Hurren TJ, Nickerson C, Hatley RH. Comparison of the delivery characteristics of dornase alpha from the I-Neb AAD system and the sidestream et nebulizer [abstract]. Pediatric Pulmonology 2008;43(S31):361.
57. Vanlaethem S, Van Ginderdeuren F, Eyns H, Malfroot A. Influence of inhaled hypertonic saline combined with airway clearance on SpO2, heart rate, dyspnoea and wet sputum weight in hospitalised CF patients [abstract]. Journal of Cystic fibrosis 2008;7 SUPPLEMENT 2:S71.
58. Denk O, Coates AL, Keller M, Leung K, Green M, Chan J, et al.Lung delivery of a new tobramycin nebuliser solution (150mg/1.5ml) by an investigational eFlow nebuliser is equivalent to TOBI but in a fraction of the time [abstract]. Journal of Cystic Fibrosis 2009;8 SUPPLEMENT 2:S66, Abstract no: 264.
59. Govoni M, Poli G, Cicirello H, Santoro D, Acerbi D, Ruzièka J. Pharmacokinetics of tobramycin nebulizer solution (Bramitob®) administered by Pari e-Flow Rapid vs Pari LC Plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection [abstract]. Journal of Cystic Fibrosis 2012;10 Suppl 1:S129, Abstract no: 285.
60. Brand P, Häussermann S, Mullinger B, Fischer A, Wachall B, Stegemann J. Reduction of drug-dose and therapy-costs in the inhalation therapy with high dose tobramycin [abstract]. Journal of Cystic Fibrosis 2006;5 SUPPLEMENT 1:S40.
61. Häussermann S, Dopfer R, Brand P, Muellinger B, Mayer Th, Scheuch G. Tobramycin serum concentrations after conventional and controlled inhalations in patients with cystic fibrosis [abstract]. American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A407.
62. McCormack P, McNamara P, Southern K. A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis. Journal of Cystic Fibrosis 2011;10(5):343-9.
63. McCormack P, McNamara PS, Southern KW. Open-label study: a comparison of breathing modes for adaptive aerosol delivery in children with cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2011;10 Suppl 1:S54, Abstract no: 214.
64. Buzzetti R, Salvatore D, Baldo E, Forneris MP, Lucidi V, Manunza D, et al.An overview of international literature from cystic fibrosis registries: Mortality and survival studies in cystic fibrosis. Journal of Cystic Fibrosis 2009;8(4):229-37.
65. Cantin A. Cystic Fibrosis lung inflammation: early, sustained and severe. American Journal of Respiratory and Critical Care Medicine 1995;151(4):939-41.
66. Cystic Fibrosis Trust. UK CF Registry Annual Data Report 2010. UK CF Registry Annual Data Report 2010.
67. Cystic Fibrosis Foundation. National Patient Registry. Annual Data Report (Bethesda, Maryland) 2006.
68. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2011 Annual Data Report. www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf (accessed 13 March 2013).
69. Conway SP, Dodd ME, Marsden RJ, Paul EA, Weller PH. Comparison of compliance in cystic fibrosis patients using either a Halolite adaptive aerosol delivery (AAD) system of a conventional high output nebuliser system [abstract]. Journal of Cystic Fibrosis 2002;1 SUPPLEMENT 1:S67, Abstract no: P161.
70. Davies J, Alton E. Monitoring respiratory disease severity in cystic fibrosis. Respiratory Care 2009;54(5):606-17.
71. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
72. European Respiratory Society Task Force. European Respiratory Society Guidelines on the use of nebulizers. European Respiratory Journal 2001;18:228-42.
73. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
74. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003428.pub2].
75. Heijerman H, Westerman E, Conway S, Touw D, Döring G, for the consensus working group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. Journal of Cystic Fibrosis 2009;8(5):295-315.
76. Henry B, Aussage P, Grosskopf C, Goehrs JM. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Quality of Life Research 2003;12(1):63-76.
77. Higgenbottam T. Key issues in nebulized drug delivery to adults. European Respiratory Review 1997;7(51):378-9.
78. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
79. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
80. Hodson M. Treatment of cystic fibrosis in the adult. Respiration 2000;67(6):595-607.
81. Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respiratory Care 2009;54(6):754-68.
82. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatric Pulomonolgy 1997;24(2):137-42.
83. O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997;52(Suppl 2):S31-S44.
84. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
85. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al.Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 2001;139(3):359-65.
86. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. Journal of Pediatrics 1998;132(4):589-95. [PUBMED: 9580754].
87. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with Cystic Fibrosis: challenges to disease self-management. Journal of Cystic Fibrosis 2009;8:91-96.
88. Zhang L, Button B, Gabriel SE, Burkett S, Yan Y, Skiadopoulos MH, et al.CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLOS Biology 2009;7(7):1-17.